BR122020020745B8 - Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende - Google Patents
Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreendeInfo
- Publication number
- BR122020020745B8 BR122020020745B8 BR122020020745A BR122020020745A BR122020020745B8 BR 122020020745 B8 BR122020020745 B8 BR 122020020745B8 BR 122020020745 A BR122020020745 A BR 122020020745A BR 122020020745 A BR122020020745 A BR 122020020745A BR 122020020745 B8 BR122020020745 B8 BR 122020020745B8
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pharmaceutical composition
- antiviral compound
- paramyxoviridae infections
- paramyxoviridae
- Prior art date
Links
- 208000002606 Paramyxoviridae Infections Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 241000711504 Paramyxoviridae Species 0.000 abstract 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- -1 riboside phosphates Chemical class 0.000 abstract 1
- 150000008223 ribosides Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
a presente invenção se refere a métodos para tratar infecções por vírus paramyxoviridae administrando ribosídeos, fosfatos de ribosídeos e pró-fármacos dos mesmos, de fórmula (i): em que a posição 1? do açúcar de nucleosídeo é substituída. os compostos, composições e métodos fornecidos são particularmente úteis para o tratamento de infecções por vírus de parainfluenza humana e sincicial respiratório.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36660910P | 2010-07-22 | 2010-07-22 | |
US61/366,609 | 2010-07-22 | ||
PCT/US2011/045102 WO2012012776A1 (en) | 2010-07-22 | 2011-07-22 | Methods and compounds for treating paramyxoviridae virus infections |
BR112013001553-5A BR112013001553B1 (pt) | 2010-07-22 | 2011-07-22 | compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem |
Publications (2)
Publication Number | Publication Date |
---|---|
BR122020020745B1 BR122020020745B1 (pt) | 2023-07-11 |
BR122020020745B8 true BR122020020745B8 (pt) | 2023-10-31 |
Family
ID=44534635
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122020020745A BR122020020745B8 (pt) | 2010-07-22 | 2011-07-22 | Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende |
BR112013001553-5A BR112013001553B1 (pt) | 2010-07-22 | 2011-07-22 | compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013001553-5A BR112013001553B1 (pt) | 2010-07-22 | 2011-07-22 | compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem |
Country Status (30)
Country | Link |
---|---|
US (6) | US20120027752A1 (pt) |
EP (1) | EP2595980B1 (pt) |
JP (2) | JP5969471B2 (pt) |
KR (2) | KR101924765B1 (pt) |
CN (2) | CN103052631B (pt) |
AP (1) | AP3269A (pt) |
AU (4) | AU2011280910B2 (pt) |
BR (2) | BR122020020745B8 (pt) |
CA (1) | CA2804840C (pt) |
CL (1) | CL2013000077A1 (pt) |
CO (1) | CO6690740A2 (pt) |
CR (2) | CR20170278A (pt) |
EA (2) | EA025252B1 (pt) |
EC (1) | ECSP13012458A (pt) |
ES (1) | ES2524356T3 (pt) |
HK (2) | HK1183487A1 (pt) |
IL (2) | IL224043A (pt) |
MA (1) | MA34470B1 (pt) |
ME (1) | ME01924B (pt) |
MX (1) | MX2013000744A (pt) |
NL (1) | NL301084I2 (pt) |
NO (1) | NO2020047I1 (pt) |
NZ (1) | NZ606156A (pt) |
PE (2) | PE20130400A1 (pt) |
PL (1) | PL2595980T3 (pt) |
PT (1) | PT2595980E (pt) |
SG (1) | SG186830A1 (pt) |
SI (1) | SI2595980T1 (pt) |
UA (1) | UA111163C2 (pt) |
WO (1) | WO2012012776A1 (pt) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101681559B1 (ko) | 2008-04-23 | 2016-12-01 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 1'-치환된 카바-뉴클레오사이드 유사체 |
WO2011035250A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
BR112012033117A2 (pt) | 2010-06-24 | 2016-11-22 | Gilead Sciences Inc | pirazolo[1,5-a]pirimidinas como agentes antivirais |
EP2596004B1 (en) | 2010-07-19 | 2014-09-10 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
MX2013000744A (es) | 2010-07-22 | 2013-03-07 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae. |
EP2794611B1 (en) | 2011-12-22 | 2017-10-11 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
AU2013235220C1 (en) * | 2011-12-22 | 2019-03-28 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN107459544B (zh) | 2011-12-22 | 2021-03-16 | 詹森生物制药有限公司 | 取代的核苷、核苷酸及其类似物 |
SI2834258T1 (sl) * | 2012-03-13 | 2017-04-26 | Gilead Sciences, Inc. | 2'-substituirani karba-nukleozidni analogi za protivirusno zdravljenje |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104583211A (zh) * | 2012-04-17 | 2015-04-29 | 吉里德科学公司 | 用于抗病毒治疗的化合物和方法 |
CN103232507B (zh) * | 2012-04-27 | 2016-07-06 | 北京大学 | 修饰核苷单体及其合成方法和应用 |
UY34824A (es) | 2012-05-25 | 2013-11-29 | Janssen R & D Ireland | Nucleósidos de espirooxetano de uracilo |
WO2014035140A2 (en) * | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
WO2014042433A2 (en) * | 2012-09-14 | 2014-03-20 | Kainos Medicine, Inc. | Compounds and compositions for modulating adenosine a3 receptor activity |
SG11201504554UA (en) | 2012-12-21 | 2015-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
EA039561B1 (ru) * | 2015-01-20 | 2022-02-10 | Джилид Сайэнс, Инк. | Соединения для лечения вирусных инфекций filoviridae |
WO2016117622A1 (ja) * | 2015-01-22 | 2016-07-28 | 国立大学法人岐阜大学 | テトラゾール誘導体及び抗ウイルス剤 |
KR20180041142A (ko) | 2015-07-22 | 2018-04-23 | 이난타 파마슈티칼스, 인코포레이티드 | Rsv 저해제로서의 벤조다이아제핀 유도체 |
US10251904B2 (en) | 2015-09-16 | 2019-04-09 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
CN108289931B (zh) | 2015-09-23 | 2022-10-11 | 默沙东公司 | 4’-取代的核苷逆转录酶抑制剂及其制备 |
KR20230111268A (ko) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
WO2017184668A1 (en) | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating flaviviridae virus infections |
WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
CN106083962B (zh) * | 2016-06-08 | 2018-12-18 | 成都倍特药业有限公司 | 一种具有环磷酰胺结构的化合物及其制备方法 |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
KR102318320B1 (ko) * | 2017-03-14 | 2021-10-27 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
EP4219513A1 (en) | 2017-05-01 | 2023-08-02 | Gilead Sciences, Inc. | Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
WO2019053696A1 (en) * | 2017-09-18 | 2019-03-21 | Alios Biopharma, Inc. | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF |
WO2019067864A1 (en) * | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV |
CN111372592A (zh) | 2017-12-07 | 2020-07-03 | 埃默里大学 | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 |
US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
SG11202110137VA (en) | 2019-03-18 | 2021-10-28 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
CA3137119A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
CN110776512A (zh) * | 2019-11-28 | 2020-02-11 | 成都傲飞生物化学品有限责任公司 | 一种核苷类似物的制备方法 |
TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
CN113214262B (zh) * | 2020-02-05 | 2023-07-07 | 华创合成制药股份有限公司 | 一种含有胍基的化合物及其制备方法和用途 |
CN113214263B (zh) * | 2020-02-06 | 2022-09-30 | 北京桦冠医药科技有限公司 | 瑞德西韦关键中间体的一种合成方法 |
US20210252027A1 (en) * | 2020-02-07 | 2021-08-19 | Cai Gu Huang | Pharmaceutical formulation containing remdesivir |
TW202315607A (zh) | 2020-02-18 | 2023-04-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
AU2021224588A1 (en) | 2020-02-18 | 2022-08-25 | Gilead Sciences, Inc. | Antiviral compounds |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
CN113292565B (zh) * | 2020-02-24 | 2023-01-31 | 浙江森科建设有限公司 | 核苷类化合物及其制备方法和应用 |
WO2021168930A1 (zh) * | 2020-02-25 | 2021-09-02 | 顾世海 | 一种瑞德西韦的片剂及其制备方法 |
WO2021175296A1 (zh) * | 2020-03-04 | 2021-09-10 | 中国科学院上海药物研究所 | 瑞德西韦的中间体及其制备方法 |
CN115298181A (zh) | 2020-03-12 | 2022-11-04 | 吉利德科学公司 | 制备1’-氰基核苷的方法 |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
CN113811309B (zh) * | 2020-04-13 | 2023-05-05 | 山东华铂凯盛生物科技有限公司 | 用于治疗病毒感染的聚合物制剂及制备方法和用途 |
US20230158074A1 (en) * | 2020-04-16 | 2023-05-25 | The General Hospital Corporation | B cell immunomodulatory therapy for acute respiratory distress syndrome |
WO2021222807A1 (en) * | 2020-04-30 | 2021-11-04 | Ajk Pharmaceutical Llc | Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals |
CN111494349A (zh) * | 2020-04-30 | 2020-08-07 | 中国人民解放军空军军医大学 | 一种瑞德西韦口腔速溶膜及制备方法 |
US20210346416A1 (en) * | 2020-05-05 | 2021-11-11 | Ralph Lipp | Pharmaceutical Compositions and Methods for their Use in Antiviral Therapy |
CN111961057A (zh) * | 2020-05-26 | 2020-11-20 | 李小冬 | 一种α构型核苷及其在治疗猫冠状病毒感染的应用 |
KR20230018473A (ko) | 2020-05-29 | 2023-02-07 | 길리애드 사이언시즈, 인코포레이티드 | 렘데시비르 치료 방법 |
US11377456B2 (en) | 2020-06-11 | 2022-07-05 | Apotex Inc. | Crystalline form of Remdesivir |
IL299202A (en) * | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
US20230263816A1 (en) * | 2020-07-17 | 2023-08-24 | Board Of Regents, The University Of Texas System | Pharmaceutical compositions for delivery of remdesivir by inhalation |
CA3185450A1 (en) | 2020-08-06 | 2022-02-10 | Istvan Borza | Remdesivir intermediates |
EP4204421A2 (en) * | 2020-08-27 | 2023-07-05 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
KR20230107288A (ko) | 2020-11-11 | 2023-07-14 | 길리애드 사이언시즈, 인코포레이티드 | gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법 |
JPWO2022107463A1 (pt) | 2020-11-18 | 2022-05-27 | ||
RU2756921C1 (ru) * | 2020-11-20 | 2021-10-07 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения ремдесивира и фосфорамидаты |
CN113735862B (zh) * | 2020-12-30 | 2024-02-02 | 南方科技大学 | 一种治疗病毒感染的核苷类化合物及其用途 |
WO2022166581A1 (zh) * | 2021-02-07 | 2022-08-11 | 石家庄迪斯凯威医药科技有限公司 | 一种核苷酸衍生物及其药物组合物和用途 |
CN112843073A (zh) * | 2021-03-30 | 2021-05-28 | 山东省农业科学院畜牧兽医研究所 | 瑞德西韦(Remdesivir)在制备抗牛副流感病毒3型药物中的应用 |
AU2022256476A1 (en) | 2021-04-16 | 2023-10-12 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
WO2022251318A1 (en) | 2021-05-26 | 2022-12-01 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
WO2023102472A1 (en) * | 2021-12-01 | 2023-06-08 | The Scripps Research Institute | Antiviral prodrugs and formulations thereof |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
WO2023161427A1 (en) | 2022-02-24 | 2023-08-31 | Eisbach Bio Gmbh | Viral combination therapy |
TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
WO2023168194A1 (en) * | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
US20240051962A1 (en) * | 2022-06-29 | 2024-02-15 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
US20240043466A1 (en) * | 2022-06-30 | 2024-02-08 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
US20240034724A1 (en) | 2022-07-01 | 2024-02-01 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1003489A (en) | 1911-04-10 | 1911-09-19 | Minnie Moritz | Barber's reversible hair-cloth. |
US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
FR2224175B1 (pt) | 1973-04-04 | 1978-04-14 | Isf Spa | |
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
ES2083580T3 (es) | 1990-06-13 | 1996-04-16 | Arnold Glazier | Profarmacos de fosforo. |
DE69129650T2 (de) | 1990-09-14 | 1999-03-25 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
DE69230613T2 (de) | 1991-07-02 | 2000-12-28 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
US6887707B2 (en) | 1996-10-28 | 2005-05-03 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
HUP0100998A3 (en) | 1998-03-03 | 2001-12-28 | Novo Nordisk As | (2e)-5-amino-5-methylhex-2-enoic acid n-methyl-n-((1r)-1-(n-methyl-n-((1r)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphtyl)ethyl)amide salts, methods for their preparation, pharmaceutical compositions comprising thereof and their use |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
WO1999049873A1 (en) | 1998-03-27 | 1999-10-07 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
AU760688B2 (en) | 1998-10-16 | 2003-05-22 | Merck Sharp & Dohme Limited | Pyrazolo-triazine derivatives as ligands for GABA receptors |
US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
JP2003514766A (ja) | 1999-06-03 | 2003-04-22 | アボット・ラボラトリーズ | 活性剤としてルイス酸を用いるオリゴヌクレオチド合成 |
AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
US6656915B1 (en) | 1999-09-15 | 2003-12-02 | Biocryst Pharmaceuticals, Inc. | Inhibiting T-cell proliferation |
WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
JP2003523978A (ja) | 2000-02-18 | 2003-08-12 | シャイアー・バイオケム・インコーポレイテッド | ヌクレオシドアナログを用いるflavivirus感染の処置もしくは予防するための方法 |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN1315862C (zh) | 2000-05-26 | 2007-05-16 | 艾登尼科斯(开曼)有限公司 | 处理黄病毒和瘟病毒的方法和组合物 |
CN1291994C (zh) | 2000-07-21 | 2006-12-27 | 吉里德科学公司 | 核苷酸膦酸酯类似物前药及其筛选和制备方法 |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
CA2426187C (en) | 2000-10-18 | 2011-08-16 | Pharmasset Limited | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
SK286630B6 (sk) | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
DE10145223A1 (de) | 2001-09-13 | 2003-04-03 | Basf Ag | Verfahren zur Herstellung von meso-Zeaxanthin |
JP2005536440A (ja) | 2001-09-28 | 2005-12-02 | イデニクス(ケイマン)リミテツド | 4’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
AT410792B (de) | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
JP2005524662A (ja) | 2002-02-28 | 2005-08-18 | ビオタ インコーポレーティッド | ヌクレオシド5’−一リン酸模倣物およびこれらのプロドラッグ |
JP2005525358A (ja) | 2002-02-28 | 2005-08-25 | ビオタ インコーポレーティッド | ヌクレオチド模倣体およびそのプロドラッグ |
US20040138170A1 (en) | 2002-03-06 | 2004-07-15 | Montgomery John A. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
RU2004135392A (ru) | 2002-05-06 | 2005-06-27 | Дженелэбс Текнолоджиз, Инк. (Us) | Производные нуклеозидов для лечения инфекции, вызываемой вирусом гепатита с |
AU2003233667A1 (en) | 2002-05-23 | 2003-12-12 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
CA2506129C (en) | 2002-11-15 | 2015-02-17 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
WO2004112687A2 (en) | 2003-06-26 | 2004-12-29 | Biotron Limited | Antiviral acylguanidine compounds and methods |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
ES2351603T3 (es) | 2003-07-25 | 2011-02-08 | Idenix Pharmaceuticals, Inc. | Análogos de nucleósidos de purina para el tratamiento de enfermedades causadas por flaviridae incluyendo hepatitis c. |
CN1863813B (zh) | 2003-08-27 | 2011-03-30 | 生物区科学管理控股有限公司 | 作为治疗剂的三环核苷或核苷酸 |
WO2005092877A1 (de) | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
EP1758453B1 (en) | 2004-06-15 | 2014-07-16 | Merck Sharp & Dohme Corp. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
WO2006002231A1 (en) | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
EP3109244B1 (en) | 2004-09-14 | 2019-03-06 | Gilead Pharmasset LLC | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
CN101043893A (zh) | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷 |
WO2006065335A2 (en) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
US8133870B2 (en) | 2004-10-29 | 2012-03-13 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
CA2587639A1 (en) | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
CA2600886A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
EP2537520A1 (en) | 2005-03-29 | 2012-12-26 | Biocryst Pharmaceuticals, Inc. | Hepatics C therapies |
TW200720285A (en) | 2005-04-25 | 2007-06-01 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
NZ610715A (en) | 2005-06-24 | 2014-07-25 | Biotron Ltd | Antiviral compounds and methods |
CN101321775B (zh) | 2005-10-03 | 2012-05-23 | 大学健康网络 | 用于治疗疟疾的odcase抑制剂 |
JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤 |
EP2133345A1 (en) | 2005-12-01 | 2009-12-16 | Basilea Pharmaceutica AG | Process for the manufacture of epoxybutanol intermediates |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
WO2007064931A2 (en) | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
EP1957510A1 (en) | 2005-12-09 | 2008-08-20 | F.Hoffmann-La Roche Ag | Antiviral nucleosides |
EP1971331A2 (en) | 2005-12-09 | 2008-09-24 | Basilea Pharmaceutica AG | 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders |
CA2637879A1 (en) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
WO2007097991A2 (en) | 2006-02-16 | 2007-08-30 | Pharmasset, Inc. | Methods and kits for dosing of antiviral agents |
DE102006015378A1 (de) | 2006-04-03 | 2007-10-04 | Ludwig-Maximilians-Universität München | Verfahren zur Synthese von Organoelementverbindungen |
AR061024A1 (es) | 2006-05-22 | 2008-07-30 | Novartis Ag | Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. |
US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
US7879806B2 (en) | 2006-11-06 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture |
CA2672613A1 (en) | 2006-12-20 | 2008-07-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
CN101611046A (zh) | 2007-01-12 | 2009-12-23 | 拜奥克里斯特制药公司 | 抗病毒的核苷类似物 |
CN101730699A (zh) | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
AU2008251555B2 (en) * | 2007-05-10 | 2012-08-30 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer |
CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
NZ583652A (en) | 2007-08-03 | 2012-06-29 | Biotron Ltd | Hepatitis c antiviral compositions and methods |
KR101502533B1 (ko) | 2007-11-22 | 2015-03-13 | 에스케이케미칼주식회사 | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 |
US20090176732A1 (en) * | 2007-12-21 | 2009-07-09 | Alios Biopharma Inc. | Protected nucleotide analogs |
TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
US8227431B2 (en) | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
KR101681559B1 (ko) | 2008-04-23 | 2016-12-01 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 1'-치환된 카바-뉴클레오사이드 유사체 |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
DK2396340T3 (en) | 2009-02-10 | 2014-03-10 | Gilead Sciences Inc | Carbanucleosidanaloge to antiviral therapy |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
EA201190178A1 (ru) * | 2009-03-20 | 2012-06-29 | Алиос Биофарма, Инк. | Замещённые нуклеозидные и нуклеотидные аналоги |
RU2489435C2 (ru) | 2009-03-24 | 2013-08-10 | Байокрист Фармасьютикалз, Инк. | Полезные фармацевтические соли 7-[(3r,4r) -3-гидрокси-4- гидроксиметил- пирролидин -1- илметил ]- 3,5- дигидро-пирроло [ 3,2-d] пиримидин-4-она |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
PE20120666A1 (es) | 2009-07-21 | 2012-06-01 | Gilead Sciences Inc | Inhibidores de los virus flaviviridae |
WO2011035250A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
ES2730805T3 (es) | 2009-09-21 | 2019-11-12 | Gilead Sciences Inc | Análogos de carba-nucleósido sustituido por 2'-fluoro para el tratamiento antiviral |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
AU2010338011B2 (en) | 2009-12-28 | 2015-04-02 | Development Center For Biotechnology | Novel pyrimidine compounds as mTOR and P13K inhibitors |
HUE034239T2 (en) | 2010-03-31 | 2018-02-28 | Gilead Pharmasset Llc | Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t |
WO2011123672A1 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Purine nucleoside phosphoramidate |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
EP2596004B1 (en) | 2010-07-19 | 2014-09-10 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
MX2013000744A (es) | 2010-07-22 | 2013-03-07 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae. |
TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
JP2013538230A (ja) | 2010-09-20 | 2013-10-10 | ギリアード サイエンシーズ, インコーポレイテッド | 抗ウイルス治療用の2’−フルオロ置換カルバヌクレオシド類似体 |
CN103209987B (zh) | 2010-09-22 | 2017-06-06 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
KR101850925B1 (ko) | 2010-10-15 | 2018-04-20 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 폴리머라아제 억제를 위한 방법 및 조성물 |
TW201701876A (zh) | 2010-12-20 | 2017-01-16 | 吉李德科學股份有限公司 | 治療c型肝炎病毒(hcv)之方法 |
AU2012242517B2 (en) | 2011-04-13 | 2016-12-15 | Gilead Sciences, Inc. | 1'-substituted pyrimidine N-nucleoside analogs for antiviral treatment |
KR20140053906A (ko) | 2011-05-13 | 2014-05-08 | 조에티스 엘엘씨 | 헨드라 및 니파 바이러스 g 당단백질 면역원성 조성물 |
SG11201400664WA (en) | 2011-09-16 | 2014-04-28 | Gilead Pharmassett Llc | Methods for treating hcv |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US20130143835A1 (en) | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
WO2013084165A1 (en) | 2011-12-05 | 2013-06-13 | Medivir Ab | Hcv polymerase inhibitors |
EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
EP2852603B1 (en) | 2012-05-22 | 2021-05-12 | Idenix Pharmaceuticals LLC | D-amino acid compounds for liver disease |
WO2014033617A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | 2'-ethynyl nucleoside derivatives for treatment of viral infections |
MA37942B1 (fr) | 2012-09-10 | 2020-01-31 | Hoffmann La Roche | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b |
WO2014042433A2 (en) | 2012-09-14 | 2014-03-20 | Kainos Medicine, Inc. | Compounds and compositions for modulating adenosine a3 receptor activity |
WO2014078778A2 (en) | 2012-11-16 | 2014-05-22 | Biocryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
WO2014078463A1 (en) | 2012-11-19 | 2014-05-22 | Merck Sharp & Dohme Corp. | 2 -alkynyl substituted nucleoside derivatives for treating viral diseases |
SG11201504554UA (en) | 2012-12-21 | 2015-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
US9283242B2 (en) | 2013-01-22 | 2016-03-15 | Massachusetts Institute Of Technology | Uses of dihydro bases |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
BR112015025716A2 (pt) | 2013-04-12 | 2017-07-18 | Achillion Pharmaceuticals Inc | pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv |
UA117375C2 (uk) | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
CN105764569B (zh) | 2013-09-11 | 2019-09-13 | 国家医疗保健研究所 | 治疗乙型肝炎病毒感染的方法和药物组合物 |
UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
EA201691261A1 (ru) | 2014-01-30 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b |
CR20160337A (es) | 2014-03-07 | 2016-09-20 | Hoffmann La Roche | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b |
CA2948080A1 (en) | 2014-05-13 | 2015-11-19 | F. Hoffmann-La Roche Ag | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection |
US9616076B2 (en) | 2014-06-02 | 2017-04-11 | The Board Of Regents Of The University Of Texas Systems | Methods for treating viral infections using hydrogen sulfide donors |
US9504701B2 (en) | 2014-06-02 | 2016-11-29 | The Board Of Regents Of The University Of Texas System | Methods for treating viral infections using hydrogen sulfide donors |
WO2016012470A1 (en) | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid |
JP6506836B2 (ja) | 2014-08-14 | 2019-04-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン |
TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
US9676793B2 (en) | 2014-12-23 | 2017-06-13 | Hoffmann-Laroche Inc. | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same |
WO2016102438A1 (en) | 2014-12-23 | 2016-06-30 | F. Hoffmann-La Roche Ag | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues |
JP6506845B2 (ja) | 2014-12-30 | 2019-04-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類 |
JP2018504891A (ja) | 2014-12-31 | 2018-02-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | リアルタイムPCRによる細胞溶解物からのHBV cccDNA定量化のための新規ハイスループット法 |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
JP2018502604A (ja) | 2015-01-27 | 2018-02-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 組換えHBV cccDNA、その作製方法およびその使用 |
EP3256471B1 (en) | 2015-02-11 | 2018-12-12 | F. Hoffmann-La Roche AG | Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection |
US10251904B2 (en) | 2015-09-16 | 2019-04-09 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
WO2017184668A1 (en) | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating flaviviridae virus infections |
CN110325187B (zh) | 2017-02-08 | 2022-09-30 | 生物环境有限公司 | N-氨基甲酰亚胺基-5-(1-甲基-1h-吡唑-4-基)-2-萘甲酰胺在制备治疗流感的药物中的用途 |
KR102318320B1 (ko) | 2017-03-14 | 2021-10-27 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
EP4219513A1 (en) | 2017-05-01 | 2023-08-02 | Gilead Sciences, Inc. | Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
CN111265532A (zh) | 2020-01-21 | 2020-06-12 | 中国人民解放军军事科学院军事医学研究院 | 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用 |
TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
CN115298181A (zh) | 2020-03-12 | 2022-11-04 | 吉利德科学公司 | 制备1’-氰基核苷的方法 |
WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
KR20230018473A (ko) | 2020-05-29 | 2023-02-07 | 길리애드 사이언시즈, 인코포레이티드 | 렘데시비르 치료 방법 |
EP4204421A2 (en) | 2020-08-27 | 2023-07-05 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
-
2011
- 2011-07-22 MX MX2013000744A patent/MX2013000744A/es active IP Right Grant
- 2011-07-22 BR BR122020020745A patent/BR122020020745B8/pt active IP Right Grant
- 2011-07-22 PE PE2013000120A patent/PE20130400A1/es active IP Right Grant
- 2011-07-22 EA EA201390152A patent/EA025252B1/ru unknown
- 2011-07-22 UA UAA201302207A patent/UA111163C2/uk unknown
- 2011-07-22 SI SI201130275T patent/SI2595980T1/sl unknown
- 2011-07-22 KR KR1020187001641A patent/KR101924765B1/ko active IP Right Grant
- 2011-07-22 CN CN201180035776.1A patent/CN103052631B/zh active Active
- 2011-07-22 CN CN201510615482.6A patent/CN105343098B/zh active Active
- 2011-07-22 SG SG2012095683A patent/SG186830A1/en unknown
- 2011-07-22 AP AP2013006680A patent/AP3269A/xx active
- 2011-07-22 BR BR112013001553-5A patent/BR112013001553B1/pt active IP Right Grant
- 2011-07-22 NZ NZ606156A patent/NZ606156A/en unknown
- 2011-07-22 WO PCT/US2011/045102 patent/WO2012012776A1/en active Application Filing
- 2011-07-22 US US13/189,373 patent/US20120027752A1/en not_active Abandoned
- 2011-07-22 PT PT117437095T patent/PT2595980E/pt unknown
- 2011-07-22 CR CR20170278A patent/CR20170278A/es unknown
- 2011-07-22 JP JP2013520895A patent/JP5969471B2/ja active Active
- 2011-07-22 MA MA35665A patent/MA34470B1/fr unknown
- 2011-07-22 AU AU2011280910A patent/AU2011280910B2/en active Active
- 2011-07-22 ES ES11743709.5T patent/ES2524356T3/es active Active
- 2011-07-22 KR KR1020137004005A patent/KR101821680B1/ko active IP Right Grant
- 2011-07-22 ME MEP-2014-148A patent/ME01924B/me unknown
- 2011-07-22 EP EP11743709.5A patent/EP2595980B1/en active Active
- 2011-07-22 PL PL11743709T patent/PL2595980T3/pl unknown
- 2011-07-22 PE PE2017001124A patent/PE20171155A1/es unknown
- 2011-07-22 CA CA2804840A patent/CA2804840C/en active Active
- 2011-07-22 EA EA201691118A patent/EA201691118A1/ru unknown
-
2012
- 2012-12-31 IL IL224043A patent/IL224043A/en active IP Right Grant
-
2013
- 2013-01-08 CL CL2013000077A patent/CL2013000077A1/es unknown
- 2013-01-10 CO CO13004212A patent/CO6690740A2/es active IP Right Grant
- 2013-02-20 CR CR20130073A patent/CR20130073A/es unknown
- 2013-02-22 EC ECSP13012458 patent/ECSP13012458A/es unknown
- 2013-09-25 HK HK13110926.3A patent/HK1183487A1/xx unknown
-
2014
- 2014-12-22 US US14/579,348 patent/US20150111839A1/en not_active Abandoned
-
2015
- 2015-02-04 US US14/613,719 patent/US10065958B2/en active Active
- 2015-10-08 AU AU2015238851A patent/AU2015238851A1/en not_active Abandoned
-
2016
- 2016-05-01 IL IL245348A patent/IL245348B/en active IP Right Grant
- 2016-07-06 JP JP2016134371A patent/JP2016216480A/ja active Pending
- 2016-08-17 HK HK16109883.3A patent/HK1221657A1/zh unknown
-
2017
- 2017-02-23 AU AU2017201230A patent/AU2017201230B2/en active Active
-
2018
- 2018-07-23 US US16/042,085 patent/US10696679B2/en active Active
-
2019
- 2019-07-23 AU AU2019208167A patent/AU2019208167B2/en active Active
-
2020
- 2020-05-20 US US16/879,491 patent/US11492353B2/en active Active
- 2020-12-23 NO NO2020047C patent/NO2020047I1/no unknown
- 2020-12-23 NL NL301084C patent/NL301084I2/nl unknown
-
2022
- 2022-06-30 US US17/854,818 patent/US20230125751A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR122020020745B8 (pt) | Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende | |
BR112013005888A2 (pt) | análogos de carba-nucleosídeo 2'-flúor substituídos para o tratamento antiviral | |
BR112013026219A2 (pt) | análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral | |
BR112015031763A2 (pt) | Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
BR112014013661A2 (pt) | Derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
UY33620A (es) | Análogos de azido nucleósidos y nucleótidos | |
MX2018003161A (es) | Metodos para tratar infecciones por virus arenaviridae y coronaviridae. | |
MD4496C1 (ro) | Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral | |
UA117095C2 (uk) | Нуклеозидна сполука або її фармацевтично прийнятна сіль | |
BR112016003348A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
EA201491493A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
WO2012158811A3 (en) | Purine monophosphate prodrugs for treatment of viral infections | |
BRPI0910455B8 (pt) | análogos de carba-nucleosídeo 1-substituído para tratamento antiviral e composição farmacêutica que os compreende | |
BR112013001267A2 (pt) | métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro | |
BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
EA201591390A1 (ru) | Пиразол[1,5-a]пиримидины для противовирусного лечения | |
UA116083C2 (uk) | Похідні пурину для лікування вірусних інфекцій | |
BR112013009029A2 (pt) | métodos e composições para inibição de polimerase | |
BR112014006559A2 (pt) | derivados do ácido betulínico com atividade antiviral | |
IN2012DN06678A (pt) | ||
BR112012007349A2 (pt) | uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas. | |
BR112014026776A2 (pt) | derivados de pirimidina para o tratamento de doenças bacterianas | |
EA201690300A1 (ru) | Замещенные аналоги пиридина-пиперазинила в качестве противовирусных соединений против rsv | |
TH141659A (th) | ไพราโซโล [1,5-a]ไพริมิดีนสำหรับการรักษาต่อต้านไวรัส | |
BR112014011347A2 (pt) | compostos para modulação de expressão de beta-catenina e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2740 DE 11/07/2023, QUANTO AO ITEM (54) TITULO. |